RxDoctor Payments Data

Ashkan Abbey, MD

Ophthalmology · Dallas, TXNPI 1548402886

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $341,731 of the $559,411 with a category attached, or 61.1%. It is spread thinly across 39 manufacturers, the largest accounting for just 21.8%. Reporting peaked in 2023 at $151,112 and has fallen 51.4% since, to $73,405 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$559,411in general payments, 2019–2025

Across 782 payments — averaging $715.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$122K
  • Apellis Pharmaceuticals, Inc.$68K
  • Genentech USA, Inc.$57K
  • Astellas Pharma US Inc$47K
  • Novartis$44K
  • Alimera Sciences, Inc.$41K
  • plus $180K from 33 others
$5,250,451in research payments, 2019–2025

Across 399 payments — averaging $13,159 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$2.6M
  • AbbVie$964K
  • Eyepoint US, Inc.$534K
  • Apellis Pharmaceuticals, Inc.$319K
  • Regeneron$185K
  • Sanofi US Services Inc.$183K
  • plus $498K from 8 others

What the payments were for

  • Consulting fees$154,79028%
  • Speaking & faculty fees$341,73161%
  • Travel & lodging$39,5727%
  • Food & beverage$23,3034%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$559,411 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$9,076,905
Medicare patients
1,633
Services billed
127,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate468$16,045
ProlensaBromfenac Sodium19$9,204
Difluprednate74$8,822
Ketorolac Tromethamine105$3,080
Bromfenac Sodium17$2,321
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat146$2,158
Gentamicin Sulfate260$1,992
Atropine Sulfate37$1,676
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$1,456
Brimonidine Tartrate81$1,254
Latanoprost29$192
Dorzolamide Hcl12$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$60$9,20419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →